NICE Recommends Xtandi, but Not Zytiga in the Pre-Chemotherapy Stage of Advanced Prostate Cancer Treatment

NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, [...]

Perhaps My Most Important Post

As we reach this holiday season I want to remind you that Malecare has been working to help you and your family survive longer and have a better quality of life. We have helped you in ways that you are aware of; like through this blog and by the Malecare Advanced Prostate Cancer Online Support Group. [...]

By |2017-10-19T10:46:42-04:00December 20th, 2015